Categorynews

Global Cephalosporin Drugs Market to Surpass US$ 19,073.1 Million by 2026

August 8, 2019 Off By BusinessWire

SEATTLE–(BUSINESS WIRE)–According to Coherent Market Insights, the global cephalosporin drugs market was valued at US$ 14,240.0 million in 2018, and is projected to exhibit a CAGR of 3.8% during the forecast period (2019 – 2026).

Key Trends and Analysis of the Cephalosporin Drugs Market:

The cephalosporin drugs market size is expected to witness a remarkable growth in the forecast period, owing to increasing approvals of new cephalosporin drugs. For instance, in March 2018, Allergan plc. announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) to expand the approved use of AVYCAZ (ceftazidime and avibactam) for the treatment of hospital-acquired bacterial pneumonia.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2893

Moreover, these increasing approval of cephalosporin drugs market is expected to generate high revenue over the forecast period, owing to increasing product launches of cephalosporin drugs. For instance, in May 2019, Ascend Laboratories launched an AB-rated generic version of Lupin’s Suprax (cefixime) oral capsules. Suprax is approved for uncomplicated urinary tract infections, otitis media, pharyngitis/tonsillitis, acute exacerbations of chronic bronchitis, and uncomplicated gonorrhea in the U.S.

Key players in the market are also focused on filing Abbreviated New Drug Applications (ANDAs) with the U.S.FDA for the approval of cephalosporin drugs. For instance, in April 2019, Lupin Limited filed two ANDAs with the U.S. FDA for Ceftriaxone injection and Cefotaxime injection in the cephalosporin segment. The filings mark the company’s entry into this segment in the U.S. generics markets & the first step towards capturing a share of the market for niche cephalosporin molecules.

Inquire before Buying @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2893

Furthermore, according to a study conducted by Balochistan University of Information Technology Engineering and Management Sciences, in July 2017, demand for Cephalosporin C is increasing worldwide due to its enhanced antibacterial spectrum and its use in the treatment of diseases and infections caused by gram positive/or gram negative bacterial strains. Cephalosporin C is easily produced from the fungus Acremonium chrysogenum by the process of fermentation in a bioreactor under optimum reaction conditions to obtain maximum yield of the antibiotic.

Buy this report (for Single User License) @ https://www.coherentmarketinsights.com/insight/buy-now/2893

Key Market Takeaways:

  • The global cephalosporin drugs market is projected to witness a CAGR of 3.8% during the forecast period (2019 – 2026), owing to increasing prevalence of bacterial infections worldwide. For instance, according to the Journal of Biomedical Sciences study report of 2013, around 2 million people suffer from hospital-acquired infections, annually and around 90,000 of these patients die as a result of these infections, worldwide.
  • Among regions, North America is expected to hold dominant position in the global cephalosporin drugs market during the forecast period, owing to increasing number of FDA approvals in the U.S. For instance, in May 2016, Allergan plc. announced that the U.S. Food and Drug Administration (FDA) approved its supplemental New Drug Application (sNDA) for TEFLARO (ceftaroline fosamil), granting new indications for pediatric patients two months of age to less than 18 years of age with acute bacterial skin and skin structure infections (ABSSSI), including infections caused by methicillin-resistant Staphylococcus aureus (MRSA).
  • Major players operating in the global cephalosporin drugs market include, Merck & Co. Inc., GlaxoSmithKline plc., Pfizer Inc., Allergan plc., Abbott Laboratories, Basilea Pharmaceutica Ltd., Sanofi S.A., F. Hoffmann-La Roche AG, Lupin Limited, Teva Pharmaceutical Industries Ltd., and B. Braun Melsungen AG

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/cephalosporin-drugs-market-2893

Report Segmention:

  • Global Cephalosporin Drugs Market, By Generation:

    • First-generation Cephalosporin
    • Second-generation Cephalosporin
    • Third-generation Cephalosporin
    • Fourth-generation Cephalosporin
    • Fifth-generation Cephalosporin
  • Global Cephalosporin Drugs Market, By Type:

    • Branded Cephalosporin Drugs
    • Generic Cephalosporin Drugs
  • Global Cephalosporin Drugs Market, By Formulation:

    • Oral
    • Injection
  • Global Cephalosporin Drugs Market, By Indication:

    • Respiratory Tract Infection
    • Skin Infection
    • Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
  • Global Cephalosporin Drugs Market, By Distribution Channel:

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Cephalosporin Drugs Market, By Region:

    • North America

      • By Country:

        • U.S.
        • Canada
    • Europe

      • By Country:

        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific

      • By Country:

        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
    • Latin America

      • By Country:

        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East

      • By Country:

        • GCC
        • Israel
        • Rest of Middle East
    • Africa

      • By Country/Region:

        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles

Contacts

Mr. Shah

Coherent Market Insights

1001 4th Ave.

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: [email protected]